2024

A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma
Balcar L, Scheiner B, Fulgenzi C, D'Alessio A, Pomej K, Roig M, Meyer E, Che J, Nishida N, Lee P, Wu L, Ang C, Krall A, Saeed A, Stefanini B, Cammarota A, Pressiani T, Abugabal Y, Chamseddine S, Wietharn B, Parisi A, Huang Y, Phen S, Vivaldi C, Salani F, Masi G, Bettinger D, Vogel A, von Felden J, Schulze K, Silletta M, Trauner M, Samson A, Wege H, Piscaglia F, Galle P, Stauber R, Kudo M, Singal A, Itani A, Ulahannan S, Parikh N, Cortellini A, Kaseb A, Rimassa L, Chon H, Pinato D, Pinter M
JHEP REP. 2024;6(2):100982.

Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours
Celsa C, Cabibbo G, Am Fulgenzi C, Scheiner B, Antonio d'Alessio , Manfredi G, Nishida N, Ang C, Marron T, Saeed A, Wietharn B, Pinter M, Cheon J, Huang Y, Lee P, Phen S, Gampa A, Pillai A, Vivaldi C, Salani F, Masi G, Roehlen N, Thimme R, Vogel A, Schönlein M, von Felden J, Schulze K, Wege H, Galle P, Kudo M, Rimassa L, Singal A, El Tomb P, Ulahannan S, Parisi A, Chon H, Hsu W, Stefanini B, Verzoni E, Giusti R, Veccia A, Catino A, Aprile G, Guglielmini P, Di Napoli M, Ermacora P, Antonuzzo L, Rossi E, Verderame F, Zustovich F, Ficorella C, Di Pietro F, Battelli N, Negrini G, Grossi F, Bordonaro R, Pipitone S, Banzi M, Ricciardi S, Laera L, Russo A, De Giorgi U, Cavanna L, Sorarù M, Montesarchio V, Bordi P, Brunetti L, Pinto C, Bersanelli M, Cammà C, Cortellini A, Pinato D
J HEPATOL. 2024;80(3):431-442.

Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment
Celsa C, Cabibbo G, Fulgenzi C, Battaglia S, Enea M, Scheiner B, D'Alessio A, Manfredi G, Stefanini B, Nishida N, Galle P, Schulze K, Wege H, Ciccia R, Hsu W, Vivaldi C, Wietharn B, Lin R, Pirozzi A, Pressiani T, Dalbeni A, Natola L, Auriemma A, Rigamonti C, Burlone M, Parisi A, Huang Y, Lee P, Ang C, Marron T, Pinter M, Cheon J, Phen S, Singal A, Gampa A, Pillai A, Roehlen N, Thimme R, Vogel A, Soror N, Ulahannan S, Sharma R, Sacerdoti D, Pirisi M, Rimassa L, Lin C, Saeed A, Masi G, Schönlein M, von Felden J, Kudo M, Cortellini A, Chon H, Cammà C, Pinato D
HEPATOLOGY. 2024 [Epub ahead of print].

Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction
Fulgenzi C, Scheiner B, D'Alessio A, Mehan A, Manfredi G, Celsa C, Nishida N, Ang C, Marron T, Wu L, Saeed A, Wietharn B, Cammarota A, Pressiani T, Pinter M, Sharma R, Cheon J, Huang Y, Lee P, Phen S, Gampa A, Pillai A, Napolitano A, Vivaldi C, Salani F, Masi G, Silletta M, Lo Prinzi F, Di Giacomo E, Vincenzi B, Bettinger D, Thimme R, Vogel A, Schönlein M, von Felden J, Schulze K, Wege H, Galle P, Pirisi M, Park J, Kudo M, Rimassa L, Singal A, El Tomb P, Ulahannan S, Parisi A, Chon H, Hsu W, Ghittoni G, Cammà C, Stefanini B, Trevisani F, Giannini E, Cortellini A, Pinato D
JAMA ONCOL. 2024;10(9):1253-1258.

Corrigendum: PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease
Kocheise L, Piseddu I, Vonderlin J, Tjwa E, Buescher G, Meunier L, Goeggelmann P, Fianchi F, Dumortier J, Barciela M, Gevers T, Beretta-Piccoli B, Londoño M, Frankova S, Roesner T, Joerg V, Schmidt C, Glaser F, Sutter J, Fründt T, Lohse A, Huber S, von Felden J, Sebode M, Schulze K
FRONT IMMUNOL. 2024;15:1369747.

Radiofrequency ablation via catheter and transpapillary access in patients with cholangiocarcinoma (ACTICCA-2 trial) - a multicenter, randomized, controlled, open-label investigator-initiated trial
Schmidt C, Zapf A, Ozga A, Canbay A, Denzer U, De Toni E, Lohse A, Schulze K, Rösch T, Stein A, Wege H, von Felden J
BMC CANCER. 2024;24(1):.

2023

Genetic variation in TERT modifies the risk of hepatocellular carcinoma in alcohol-related cirrhosis: results from a genome-wide case-control study
Buch S, Innes H, Lutz P, Nischalke H, Marquardt J, Fischer J, Weiss K, Rosendahl J, Marot A, Krawczyk M, Casper M, Lammert F, Eyer F, Vogel A, Marhenke S, von Felden J, Sharma R, Atkinson S, McQuillin A, Nattermann J, Schafmayer C, Franke A, Strassburg C, Rietschel M, Altmann H, Sulk S, Thangapandi V, Brosch M, Lackner C, Stauber R, Canbay A, Link A, Reiberger T, Mandorfer M, Semmler G, Scheiner B, Datz C, Romeo S, Ginanni Corradini S, Irving W, Morling J, Guha I, Barnes E, Ansari M, Quistrebert J, Valenti L, Müller S, Morgan M, Dufour J, Trebicka J, Berg T, Deltenre P, Mueller S, Hampe J, Stickel F
GUT. 2023;72(2):381-391.

Long-term persistence of HCV resistance-associated substitutions after DAA treatment failure
Dietz J, Müllhaupt B, Buggisch P, Graf C, Peiffer K, Matschenz K, Schattenberg J, Antoni C, Mauss S, Niederau C, Discher T, Trauth J, Dultz G, Schulze Zur Wiesch J, Piecha F, Klinker H, Müller T, Berg T, Neumann-Haefelin C, Berg C, Zeuzem S, Sarrazin C
J HEPATOL. 2023;78(1):57-66.

Tissue resident iNKT17 cells facilitate cancer cell extravasation in liver metastasis via interleukin-22
Giannou A, Kempski J, Shiri A, Lücke J, Zhang T, Zhao L, Zazara D, Cortesi F, Riecken K, Amezcua Vesely M, Low J, Xu H, Kaffe E, Garcia-Perez L, Agalioti T, Yamada Y, Jungraithmayr W, Zigmond E, Karstens K, Steglich B, Wagner J, Konczalla L, Carambia A, Schulze K, von Felden J, May P, Briukhovetska D, Bedke T, Brockmann L, Starzonek S, Lange T, Koch C, Riethdorf S, Pelczar P, Böttcher M, Sabihi M, Huber F, Reeh M, Grass J, Wahib R, Seese H, Stüben B, Fard-Aghaie M, Duprée A, Scognamiglio P, Plitzko G, Meiners J, Soukou S, Wittek A, Manthey C, Maroulis I, Arck P, Perez D, Gao B, Zarogiannis S, Strowig T, Pasqualini R, Arap W, Gosálvez J, Kobold S, Prinz I, Guse A, Tachezy M, Ghadban T, Heumann A, Li J, Melling N, Mann O, Izbicki J, Pantel K, Schumacher U, Lohse A, Flavell R, Gagliani N, Huber S
IMMUNITY. 2023;56(1):125-142.e12.

Efficacy and safety of atezolizumab/bevacizumab in patients with HCC after prior systemic therapy: A global, observational study
Joerg V, Scheiner B, D Alessio A, Fulgenzi C, Schönlein M, Kocheise L, Lohse A, Huber S, Wege H, Kaseb A, Wang Y, Mathew A, Kuang A, Muzaffar M, Abugabal Y, Chamseddine S, Phen S, Cheon J, Lee P, Balcar L, Krall A, Ang C, Wu L, Saeed A, Huang Y, Bengsch B, Rimassa L, Weinmann A, Stauber R, Korolewicz J, Pinter M, Singal A, Chon H, Pinato D, Schulze K, von Felden J
HEPATOL COMMUN. 2023;7(11):.

PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease
Kocheise L, Piseddu I, Vonderlin J, Tjwa E, Buescher G, Meunier L, Goeggelmann P, Fianchi F, Dumortier J, Riveiro Barciela M, Gevers T, Terziroli Beretta-Piccoli B, Londoño M, Frankova S, Roesner T, Joerg V, Schmidt C, Glaser F, Sutter J, Fründt T, Lohse A, Huber S, von Felden J, Sebode M, Schulze K
FRONT IMMUNOL. 2023;14:1326078.

EpCAM-positive circulating tumor cells and serum AFP levels predict outcome after curative resection of hepatocellular carcinoma
Kocheise L, Schoenlein M, Behrends B, Joerg V, Casar C, Fründt T, Renné T, Heumann A, Li J, Huber S, Lohse A, Pantel K, Riethdorf S, Wege H, Schulze K, von Felden J
SCI REP-UK. 2023;13(1):20827.

Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma
Scheiner B, Roessler D, Phen S, Lim M, Pomej K, Pressiani T, Cammarota A, Fründt T, von Felden J, Schulze K, Himmelsbach V, Finkelmeier F, Deibel A, Siebenhüner A, Shmanko K, Radu P, Schwacha-Eipper B, Ebert M, Teufel A, Djanani A, Hucke F, Balcar L, Philipp A, Hsiehchen D, Venerito M, Sinner F, Trauner M, D'Alessio A, Fulgenzi C, Pinato D, Peck-Radosavljevic M, Dufour J, Weinmann A, Kremer A, Singal A, De Toni E, Rimassa L, Pinter M
JHEP REP. 2023;5(1):.

Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma
Vithayathil M, D'Alessio A, Fulgenzi C, Nishida N, Schönlein M, von Felden J, Schulze K, Wege H, Saeed A, Wietharn B, Hildebrand H, Wu L, Ang C, Marron T, Weinmann A, Galle P, Bettinger D, Bengsch B, Vogel A, Balcar L, Scheiner B, Lee P, Huang Y, Amara S, Muzaffar M, Naqash A, Cammarota A, Zanuso V, Pressiani T, Pinter M, Cortellini A, Kudo M, Rimassa L, Pinato D, Sharma R
HEPATOL INT. 2023;17(4):904-914.

2022

Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: a real-world study
D'Alessio A, Fulgenzi C, Nishida N, Schönlein M, von Felden J, Schulze K, Wege H, Gaillard V, Saeed A, Wietharn B, Hildebrand H, Wu L, Ang C, Marron T, Weinmann A, Galle P, Bettinger D, Bengsch B, Vogel A, Balcar L, Scheiner B, Lee P, Huang Y, Amara S, Muzaffar M, Naqash A, Cammarota A, Personeni N, Pressiani T, Sharma R, Pinter M, Cortellini A, Kudo M, Rimassa L, Pinato D
HEPATOLOGY. 2022;76(4):1000-1012.

Equal Efficacy and Safety Profile in Elderly Patients with Hepatocellular Carcinoma Receiving Palliative Treatment
Fründt T, Casar C, von Felden J, Schöler U, Priebe M, Kraczyk J, Ahrend H, Salamon J, Adam G, Huber S, Lohse A, Wege H, Schulze K
CANCERS. 2022;14(3):.

Circulating tumor cells as a preoperative risk marker for occult metastases in patients with resectable cholangiocarcinoma
Fründt T, von Felden J, Krause J, Heumann A, Li J, Riethdorf S, Pantel K, Huber S, Lohse A, Wege H, Schulze K
FRONT ONCOL. 2022;12:.

Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study
Fulgenzi C, Cheon J, D'Alessio A, Nishida N, Ang C, Marron T, Wu L, Saeed A, Wietharn B, Cammarota A, Pressiani T, Personeni N, Pinter M, Scheiner B, Balcar L, Napolitano A, Huang Y, Phen S, Naqash A, Vivaldi C, Salani F, Masi G, Bettinger D, Vogel A, Schönlein M, von Felden J, Schulze K, Wege H, Galle P, Kudo M, Rimassa L, Singal A, Sharma R, Cortellini A, Gaillard V, Chon H, Pinato D
EUR J CANCER. 2022;175:204-213.

A Critical Role of the IL-22-IL-22 Binding Protein Axis in Hepatocellular Carcinoma
Giannou A, Lücke J, Kleinschmidt D, Shiri A, Steglich B, Nawrocki M, Zhang T, Zazara D, Kempski J, Zhao L, Giannou O, Agalioti T, Brockmann L, Bertram F, Sabihi M, Böttcher M, Ewald F, Schulze K, von Felden J, Machicote A, Maroulis I, Arck P, Graß J, Mercanoglu B, Reeh M, Wolter S, Tachezy M, Seese H, Theodorakopoulou M, Lykoudis P, Heumann A, Uzunoglu F, Ghadban T, Mann O, Izbicki J, Li J, Duprée A, Melling N, Gagliani N, Huber S
CANCERS. 2022;14(24):.

The rs429358 Locus in Apolipoprotein E Is Associated With Hepatocellular Carcinoma in Patients With Cirrhosis
Innes H, Nischalke H, Guha I, Weiss K, Irving W, Gotthardt D, Barnes E, Fischer J, Ansari M, Rosendahl J, Lin S, Marot A, Pedergnana V, Casper M, Benselin J, Lammert F, McLauchlan J, Lutz P, Hamill V, Mueller S, Morling J, Semmler G, Eyer F, von Felden J, Link A, Vogel A, Marquardt J, Sulk S, Trebicka J, Valenti L, Datz C, Reiberger T, Schafmayer C, Berg T, Deltenre P, Hampe J, Stickel F, Buch S
HEPATOL COMMUN. 2022;6(5):1213-1226.

Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score
Scheiner B, Pomej K, Kirstein M, Hucke F, Finkelmeier F, Waidmann O, Himmelsbach V, Schulze K, von Felden J, Fründt T, Stadler M, Heinzl H, Shmanko K, Spahn S, Radu P, Siebenhüner A, Mertens J, Rahbari N, Kütting F, Waldschmidt D, Ebert M, Teufel A, De Dosso S, Pinato D, Pressiani T, Meischl T, Balcar L, Müller C, Mandorfer M, Reiberger T, Trauner M, Personeni N, Rimassa L, Bitzer M, Trojan J, Weinmann A, Wege H, Dufour J, Peck-Radosavljevic M, Vogel A, Pinter M
J HEPATOL. 2022;76(2):353-363.

Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma
Vithayathil M, D'Alessio A, Fulgenzi C, Nishida N, Schönlein M, von Felden J, Schulze K, Wege H, Saeed A, Wietharn B, Hildebrand H, Wu L, Ang C, Marron T, Weinmann A, Galle P, Bettinger D, Bengsch B, Vogel A, Balcar L, Scheiner B, Lee P, Huang Y, Amara S, Muzaffar M, Naqash A, Cammarota A, Personeni N, Pressiani T, Pinter M, Cortellini A, Kudo M, Rimassa L, Pinato D, Sharma R
LIVER INT. 2022;42(11):2538-2547.

Erratum zu: Milde COVID-19-Verläufe bei Mitarbeitenden einer Universitätsklinik : Die „erste Welle“ am Universitätsklinikum Hamburg-Eppendorf
von Felden J, Brehm T, Schulze Zur Wiesch J, Addo M, Lohse A, Knobloch J, Koch T
BUNDESGESUNDHEITSBLA. 2022;65(3):398.

Unannotated small RNA clusters associated with circulating extracellular vesicles detect early stage liver cancer
von Felden J, Garcia-Lezana T, Dogra N, Gonzalez-Kozlova E, Ahsen M, Craig A, Gifford S, Wunsch B, Smith J, Kim S, Diaz J, Chen X, Labgaa I, Haber P, Olsen R, Han D, Restrepo P, D'Avola D, Hernandez-Meza G, Allette K, Sebra R, Saberi B, Tabrizian P, Asgharpour A, Dieterich D, Llovet J, Cordon-Cardo C, Tewari A, Schwartz M, Stolovitzky G, Losic B, Villanueva A
GUT. 2022;71(10):2069-2080.

Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab
Wu Y, Fulgenzi C, D'Alessio A, Cheon J, Nishida N, Saeed A, Wietharn B, Cammarota A, Pressiani T, Personeni N, Pinter M, Scheiner B, Balcar L, Huang Y, Phen S, Naqash A, Vivaldi C, Salani F, Masi G, Bettinger D, Vogel A, Schönlein M, von Felden J, Schulze K, Wege H, Galle P, Kudo M, Rimassa L, Singal A, Sharma R, Cortellini A, Gaillard V, Chon H, Pinato D, Ang C
CANCERS. 2022;14(23):.

2021

Transcriptomic characterization of cancer-testis antigens identifies MAGEA3 as a driver of tumor progression in hepatocellular carcinoma
Craig A, Garcia-Lezana T, Ruiz de Galarreta M, Villacorta-Martin C, Kozlova E, Martins-Filho S, von Felden J, Ahsen M, Bresnahan E, Hernandez-Meza G, Labgaa I, D'Avola D, Schwartz M, Llovet J, Sia D, Thung S, Losic B, Lujambio A, Villanueva A
PLOS GENET. 2021;17(6):.

Diagnostic and Prognostic Value of miR-16, miR-146a, miR-192 and miR-221 in Exosomes of Hepatocellular Carcinoma and Liver Cirrhosis Patients
Fründt T, Krause L, Hussey E, Steinbach B, Köhler D, von Felden J, Schulze K, Lohse A, Wege H, Schwarzenbach H
CANCERS. 2021;13(10):2484.

DNA methylation profiling of human hepatocarcinogenesis
Hernandez-Meza G, von Felden J, Gonzalez-Kozlova E, Garcia-Lezana T, Peix J, Portela A, Craig A, Sayols S, Schwartz M, Losic B, Mazzaferro V, Esteller M, Llovet J, Villanueva A
HEPATOLOGY. 2021;74(1):183-199.

Experimental Models of Liquid Biopsy in Hepatocellular Carcinoma Reveal Clone-Dependent Release of Circulating Tumor DNA
Labgaa I, von Felden J, Craig A, Martins-Filho S, Villacorta-Martin C, Demartines N, Dormond O, D'Avola D, Villanueva A
HEPATOL COMMUN. 2021;5(6):1095-1105.

Early Detection of Hepatocellular Carcinoma Since the Introduction of the German Clinical Practice Guideline in 2013
Schulze K, Felden J, Fründt T, Krause J, Werner T, Casar C, Jung C, Ittrich H, Sterneck M, Li J, Heumann A, Fischer L, Adam G, Lohse A, Wege H
DTSCH ARZTEBL INT. 2021;118(31-32):540-541.

Milde COVID-19-Verläufe bei Mitarbeitenden einer Universitätsklinik: Die „erste Welle“ am Universitätsklinikum Hamburg-Eppendorf
von Felden J, Brehm T, Schulze-Zur-Wiesch J, Addo M, Lohse A, Knobloch J, Koch T
BUNDESGESUNDHEITSBLA. 2021;64(9):1165-1168.

Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma
von Felden J, Craig A, Garcia-Lezana T, Labgaa I, Haber P, D'Avola D, Asgharpour A, Dieterich D, Bonaccorso A, Torres-Martin M, Sia D, Sung M, Tabrizian P, Schwartz M, Llovet J, Villanueva A
ONCOGENE. 2021;40(1):140-151.

Sequential Systemic Treatment in Advanced Hepatocellular Carcinoma Is Able to Prolong Median Survival to More than 3 Years in a Selected Real-World Cohort
von Felden J, Karkmann K, Ittrich H, Gil-Ibanez I, Fründt T, Krause J, Lohse A, Wege H, Schulze K
VISC MED. 2021;37(2):87-93.

Rare variants of primary liver cancer: Fibrolamellar, combined, and sarcomatoid hepatocellular carcinomas
Wege H, Schulze K, von Felden J, Calderaro J, Reig M
EUR J MED GENET. 2021;64(11):.

2020

GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis
Best J, Bechmann L, Sowa J, Sydor S, Dechêne A, Pflanz K, Bedreli S, Schotten C, Geier A, Berg T, Fischer J, Vogel A, Bantel H, Weinmann A, Schattenberg J, Huber Y, Wege H, von Felden J, Schulze K, Bettinger D, Thimme R, Sinner F, Schütte K, Weiss K, Toyoda H, Yasuda S, Kumada T, Berhane S, Wichert M, Heider D, Gerken G, Johnson P, Canbay A
CLIN GASTROENTEROL H. 2020;18(3):728-735.e4.

High rates of cirrhosis and severe clinical events in patients with HBV/HDV co-infection:longitudinal analysis of a German cohort:longitudinal analysis of a German cohort
Bockmann J, Grube M, Hamed V, von Felden J, Landahl J, Wehmeyer M, Giersch K, Hall M, Murray J, Dandri M, Lüth S, Lohse A, Lütgehetmann M, Schulze Zur Wiesch J
BMC GASTROENTEROL. 2020;20(1):24.

Tumour evolution in hepatocellular carcinoma
Craig A, von Felden J, Garcia-Lezana T, Sarcognato S, Villanueva A
NAT REV GASTRO HEPAT. 2020;17(3):139-152.

Hepatocellular carcinoma: Intratumoral EpCAM-positive cancer stem cell heterogeneity identifies high-risk tumor subtype
Krause J, von Felden J, Casar C, Fründt T, Galaski J, Schmidt C, Jung C, Ittrich H, Weidemann S, Krech T, Heumann A, Li J, Fischer L, Sauter G, Lohse A, Wege H, Schulze K
BMC CANCER. 2020;20(1):1130.

Intratumoral heterogeneity and clonal evolution in liver cancer
Losic B, Craig A, Villacorta-Martin C, Martins-Filho S, Akers N, Chen X, Ahsen M, von Felden J, Labgaa I, DʹAvola D, Allette K, Lira S, Furtado G, Garcia-Lezana T, Restrepo P, Stueck A, Ward S, Fiel M, Hiotis S, Gunasekaran G, Sia D, Schadt E, Sebra R, Schwartz M, Llovet J, Thung S, Stolovitzky G, Villanueva A
NAT COMMUN. 2020;11(1):291.

Treatment and re-treatment results of HCV patients in the DAA era
Piecha F, Gänßler J, Ozga A, Wehmeyer M, Dietz J, Kluwe J, Laschtowitz A, von Felden J, Sterneck M, Jordan S, Pischke S, Lohse A, Schulze Zur Wiesch J
PLOS ONE. 2020;15(5):e0232773.

Genetic variation in HSD17B13 reduces the risk of developing cirrhosis and hepatocellular carcinoma in alcohol misusers
Stickel F, Lutz P, Buch S, Nischalke H, Silva I, Rausch V, Fischer J, Weiss K, Gotthardt D, Rosendahl J, Marot A, Elamly M, Krawczyk M, Casper M, Lammert F, Buckley T, McQuillin A, Spengler U, Eyer F, Vogel A, Marhenke S, von Felden J, Wege H, Sharma R, Atkinson S, Franke A, Nehring S, Moser V, Schafmayer C, Spahr L, Lackner C, Stauber R, Canbay A, Link A, Valenti L, Grove J, Aithal G, Marquardt J, Fateen W, Zopf S, Dufour J, Trebicka J, Datz C, Deltenre P, Mueller S, Berg T, Hampe J, Morgan M
HEPATOLOGY. 2020;72(1):88-102.

New systemic agents for hepatocellular carcinoma: an update 2020
von Felden J
CURR OPIN GASTROEN. 2020;36(3):177-183.

Liquid biopsy in the clinical management of hepatocellular carcinoma
von Felden J, Garcia-Lezana T, Schulze K, Losic B, Villanueva A
GUT. 2020;69(11):2025-2034.

Role of Molecular Biomarkers in Liver Transplantation for Hepatocellular Carcinoma
von Felden J, Villanueva A
LIVER TRANSPLANT. 2020;26(6):823-831.

Elevated Aspartate Aminotransferase to Alanine Aminotransferase Ratio Predicts Poor Outcome in Hepatocellular Carcinoma
von Felden J, Wege H, Schulze K
HEPATOL COMMUN. 2020;4(9):1382-1383.

2019

Detection of a Broad Range of Low-Level Major Histocompatibility Complex Class II-Restricted, Hepatitis Delta Virus (HDV)-Specific T-Cell Responses Regardless of Clinical Status
Landahl J, Bockmann J, Scheurich C, Ackermann C, Matzat V, Heide J, Nuurei T, D'Antonio G, von Felden J, Sette A, Peine S, Lohse A, Lütgehetmann M, Marget M, Sidney J, Schulze Zur Wiesch J
J INFECT DIS. 2019;219(4):568-577.

Chronic Hepatitis E in Rheumatology and Internal Medicine Patients: A Retrospective Multicenter European Cohort Study
Pischke S, Peron J, von Wulffen M, von Felden J, Höner Zu Siederdissen C, Fournier S, Lütgehetmann M, Iking-Konert C, Bettinger D, Par G, Thimme R, Cantagrel A, Lohse A, Wedemeyer H, de Man R, Mallet V
VIRUSES-BASEL. 2019;11(2):.

β-Catenin Activation Promotes Immune Escape and Resistance to Anti-PD-1 Therapy in Hepatocellular Carcinoma
Ruiz de Galarreta M, Bresnahan E, Molina-Sánchez P, Lindblad K, Maier B, Sia D, Puigvehi M, Miguela V, Casanova-Acebes M, Dhainaut M, Villacorta-Martin C, Singhi A, Moghe A, von Felden J, Tal Grinspan L, Wang S, Kamphorst A, Monga S, Brown B, Villanueva A, Llovet J, Merad M, Lujambio A
CANCER DISCOV. 2019;9(8):1124-1141.

Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort
Scheiner B, Kirstein M, Hucke F, Finkelmeier F, Schulze K, von Felden J, Koch S, Schwabl P, Hinrichs J, Waneck F, Waidmann O, Reiberger T, Müller C, Sieghart W, Trauner M, Weinmann A, Wege H, Trojan J, Peck-Radosavljevic M, Vogel A, Pinter M
ALIMENT PHARM THER. 2019;49(10):1323-1333.

Heterozygous carriage of the alpha1-antitrypsin Pi*Z variant increases the risk to develop liver cirrhosis
Strnad P, Buch S, Hamesch K, Fischer J, Rosendahl J, Schmelz R, Brueckner S, Brosch M, Heimes C, Woditsch V, Scholten D, Nischalke H, Janciauskiene S, Mandorfer M, Trauner M, Way M, McQuillin A, Reichert M, Krawczyk M, Casper M, Lammert F, Braun F, von Schönfels W, Hinz S, Burmeister G, Hellerbrand C, Teufel A, Feldman A, Schattenberg J, Bantel H, Pathil A, Demir M, Kluwe J, Boettler T, Ridinger M, Wodarz N, Soyka M, Rietschel M, Weber T, Marhenke S, Vogel A, Hinrichsen H, Canbay A, Schlattjan M, Sosnowsky K, Sarrazin C, von Felden J, Geier A, Deltenre P, Sipos B, Schafmayer C, Nothnagel M, Aigner E, Datz C, Stickel F, Morgan M, Hampe J, Berg T, Trautwein C
GUT. 2019;68(6):1099-1107.

The burden of hepatitis E among patients with haematological malignancies: A retrospective European cohort study
von Felden J, Alric L, Pischke S, Aitken C, Schlabe S, Spengler U, Giordani M, Schnitzler P, Bettinger D, Thimme R, Xhaard A, Binder M, Ayuk F, Lohse A, Cornelissen J, de Man R, Mallet V
J HEPATOL. 2019;71(3):465-472.

The Impact of Translational Research in Hepatology
von Felden J, Craig A, Villanueva A
Clin Liver Dis (Hoboken). 2019;13(1):29-33.

Reply to: "Burden of hepatitis E infection and associated healthcare resource utilization among hematological malignancy-related hospitalizations: A national perspective in the United States, 2007-2014"
von Felden J, Mallet V, Pischke S
J HEPATOL. 2019;71(6):1268-1269.

2018

High-density single cell mRNA sequencing to characterize circulating tumor cells in hepatocellular carcinoma
D'Avola D, Villacorta-Martin C, Martins-Filho S, Craig A, Labgaa I, von Felden J, Kimaada A, Bonaccorso A, Tabrizian P, Hartmann B, Sebra R, Schwartz M, Villanueva A
SCI REP-UK. 2018;8:11570.

Levels of Cytokines in Serum Associate With Development of Hepatocellular Carcinoma in Patients With HCV Infection Treated With Direct-Acting Antivirals
Debes J, van Tilborg M, Groothuismink Z, Hansen B, Schulze Zur Wiesch J, von Felden J, de Knegt R, Boonstra A
GASTROENTEROLOGY. 2018;154(3):515-517.

Usefulness of biochemical remission and transient elastography in monitoring disease course in autoimmune hepatitis
Hartl J, Ehlken H, Sebode M, Peiseler M, Krech T, Zenouzi R, von Felden J, Weiler-Normann C, Schramm C, Lohse A
J HEPATOL. 2018;68(4):754-763.

A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma
Labgaa I, Villacorta-Martin C, D'Avola D, Craig A, von Felden J, Martins-Filho S, Sia D, Stueck A, Ward S, Fiel M, Mahajan M, Tabrizian P, Thung S, Ang C, Friedman S, Llovet J, Schwartz M, Villanueva A
ONCOGENE. 2018;37(27):3740-3752.

Correction: Genetic Variants in PNPLA3 and TM6SF2 Predispose to the Development of Hepatocellular Carcinoma in Individuals With Alcohol-Related Cirrhosis
Stickel F, Buch S, Nischalke H, Weiss K, Gotthardt D, Fischer J, Rosendahl J, Marot A, Elamly M, Casper M, Lammert F, McQuillin A, Zopf S, Spengler U, Marhenke S, Kirstein M, Vogel A, Eyer F, von Felden J, Wege H, Buch T, Schafmayer C, Braun F, Deltenre P, Berg T, Morgan M, Hampe J
AM J GASTROENTEROL. 2018;113(7):1099.

Genetic variants in PNPLA3 and TM6SF2 predispose to the development of hepatocellular carcinoma in individuals with alcohol-related cirrhosis
Stickel F, Buch S, Nischalke H, Weiss K, Gotthardt D, Fischer J, Rosendahl J, Marot A, Elamly M, Casper M, Lammert F, McQuillin A, Zopf S, Spengler U, Marhenke S, Kirstein M, Vogel A, Eyer F, von Felden J, Wege H, Buch T, Schafmayer C, Braun F, Deltenre P, Berg T, Morgan M, Hampe J
AM J GASTROENTEROL. 2018;113(10):1475-1483.

Role of circulating tumor DNA to help decision-making in hepatocellular carcinoma
von Felden J, Craig A, Villanueva A
Oncoscience. 2018;5(7-8):209-211.

Successful treatment of chronic hepatitis C with ground ledipasvir/sofosbuvir in a patient with Crohn's disease and short bowel syndrome
von Felden J, Scheurich C, Yamamura J, Brainard D, Mogalian E, Lohse A, Schulze Zur Wiesch J
J VIRAL HEPATITIS. 2018;25(2):214-215.

High efficacy of sofosbuvir/velpatasvir and impact of baseline resistance-associated substitutions in hepatitis C genotype 3 infection
von Felden J, Vermehren J, Ingiliz P, Mauss S, Lutz T, Simon K, Busch H, Baumgarten A, Schewe K, Hueppe D, Boesecke C, Rockstroh J, Daeumer M, Luebke N, Timm J, Schulze Zur Wiesch J, Sarrazin C, Christensen S
ALIMENT PHARM THER. 2018;47(9):1288-1295.

Editorial: genotype 3 HCV-who still needs ribavirin in a pan-genotypic era? Authors' reply.
von Felden J, Vermehren J, Schulze Zur Wiesch J, Sarrazin C, Christensen S
ALIMENT PHARM THER. 2018;47(11):1550-1551.

2017

Molecular profiling of liver cancer heterogeneity
Craig A, von Felden J, Villanueva A
DISCOV MED. 2017;24(131):117-125.

High expression of micro RNA-135A in hepatocellular carcinoma is associated with recurrence within 12 months after resection
von Felden J, Heim D, Schulze K, Krech T, Ewald F, Nashan B, Lohse A, Wege H
BMC CANCER. 2017;17(1):60.

Circulating tumor cells as liquid biomarker for high HCC recurrence risk after curative liver resection
von Felden J, Schulze K, Krech T, Ewald F, Nashan B, Pantel K, Lohse A, Riethdorf S, Wege H
ONCOTARGET. 2017;8(52):89978-89987.

2016

First- and Second-Line Targeted Systemic Therapy in Hepatocellular Carcinoma-An Update on Patient Selection and Response Evaluation
von Felden J, Schulze K, Gil-Ibanez I, Werner T, Wege H
DIAGNOSTICS. 2016;6(4):E44.

2015

MAP-Kinase Activated Protein Kinase 2 Links Endothelial Activation and Monocyte/macrophage Recruitment in Arteriogenesis
Limbourg A, von Felden J, Jagavelu K, Krishnasamy K, Napp L, Kapopara P, Gaestel M, Schieffer B, Bauersachs J, Limbourg F, Bavendiek U
PLOS ONE. 2015;10(10):e0138542.

2014

Mitogen-activated protein kinase-activated protein kinase 2 deficiency reduces insulin sensitivity in high-fat diet-fed mice
de Boer J, Dikkers A, Jurdzinski A, von Felden J, Gaestel M, Bavendiek U, Tietge U
PLOS ONE. 2014;9(9):e106300.

Deficiency of MAPK-activated protein kinase 2 (MK2) prevents adverse remodelling and promotes endothelial healing after arterial injury
Kapopara P, von Felden J, Soehnlein O, Wang Y, Napp L, Sonnenschein K, Wollert K, Schieffer B, Gaestel M, Bauersachs J, Bavendiek U
THROMB HAEMOSTASIS. 2014;112(6):1264-76.

2013

Drug-induced acute liver injury mimicking autoimmune hepatitis after intake of dietary supplements containing glucosamine and chondroitin sulfate
von Felden J, Montani M, Kessebohm K, Stickel F
INT J CLIN PHARM TH. 2013;51(3):219-23.

2012

Transsignaling of interleukin-6 crucially contributes to atherosclerosis in mice
Schuett H, Oestreich R, Waetzig G, Annema W, Luchtefeld M, Hillmer A, Bavendiek U, von Felden J, Divchev D, Kempf T, Wollert K, Seegert D, Rose-John S, Tietge U, Schieffer B, Grote K
ARTERIOSCL THROM VAS. 2012;32(2):281-90.

Letzte Aktualisierung aus dem FIS: 04.11.2024 - 23:35 Uhr